191 related articles for article (PubMed ID: 24038157)
21. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.
Huang SP; Lévesque E; Guillemette C; Yu CC; Huang CY; Lin VC; Chung IC; Chen LC; Laverdière I; Lacombe L; Fradet Y; Chang TY; Lee HZ; Juang SH; Bao BY
Int J Cancer; 2014 Dec; 135(11):2661-7. PubMed ID: 24740842
[TBL] [Abstract][Full Text] [Related]
22. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
23. Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium.
Mondul AM; Shui IM; Yu K; Travis RC; Stevens VL; Campa D; Schumacher FR; Ziegler RG; Bueno-de-Mesquita HB; Berndt S; Crawford ED; Gapstur SM; Gaziano JM; Giovannucci E; Haiman CA; Henderson BE; Hunter DJ; Johansson M; Key TJ; Le Marchand L; Lindström S; McCullough ML; Navarro C; Overvad K; Palli D; Purdue M; Stampfer MJ; Weinstein SJ; Willett WC; Yeager M; Chanock SJ; Trichopoulos D; Kolonel LN; Kraft P; Albanes D
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):688-96. PubMed ID: 23377224
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.
Cole AI; Morgan TM; Spratt DE; Palapattu GS; He C; Tomlins SA; Weizer AZ; Feng FY; Wu A; Siddiqui J; Chinnaiyan AM; Montgomery JS; Kunju LP; Miller DC; Hollenbeck BK; Wei JT; Mehra R
J Urol; 2016 Aug; 196(2):405-11. PubMed ID: 26920466
[TBL] [Abstract][Full Text] [Related]
25. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
[TBL] [Abstract][Full Text] [Related]
26. Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy.
Cotignola J; Leonardi DB; Shahabi A; Acuña AD; Stern MC; Navone N; Scorticati C; De Siervi A; Mazza O; Vazquez E
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):28-34. PubMed ID: 23146971
[TBL] [Abstract][Full Text] [Related]
27. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Albanes D; Till C; Klein EA; Goodman PJ; Mondul AM; Weinstein SJ; Taylor PR; Parnes HL; Gaziano JM; Song X; Fleshner NE; Brown PH; Meyskens FL; Thompson IM
Cancer Prev Res (Phila); 2014 Sep; 7(9):886-95. PubMed ID: 24961880
[TBL] [Abstract][Full Text] [Related]
28. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.
Dluzniewski PJ; Wang MH; Zheng SL; De Marzo AM; Drake CG; Fedor HL; Partin AW; Han M; Fallin MD; Xu J; Isaacs WB; Platz EA
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1774-82. PubMed ID: 22859398
[TBL] [Abstract][Full Text] [Related]
29. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
Nanda A; Chen MH; Renshaw AA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
[TBL] [Abstract][Full Text] [Related]
30. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
31. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
32. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.
Stroup SP; Moreira DM; Chen Z; Howard L; Berger JH; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
J Urol; 2017 Dec; 198(6):1309-1315. PubMed ID: 28709888
[TBL] [Abstract][Full Text] [Related]
33. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
35. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.
Li H; Kantoff PW; Giovannucci E; Leitzmann MF; Gaziano JM; Stampfer MJ; Ma J
Cancer Res; 2005 Mar; 65(6):2498-504. PubMed ID: 15781667
[TBL] [Abstract][Full Text] [Related]
36. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
37. Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer.
Reis ST; Viana NI; Leite KR; Diogenes E; Antunes AA; Iscaife A; Nesrallah AJ; Passerotti CC; Srougi V; Pontes-Junior J; Salles ME; Nahas WC; Srougi M
PLoS One; 2016; 11(12):e0166380. PubMed ID: 27906997
[TBL] [Abstract][Full Text] [Related]
38. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
39. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk.
Cooper ML; Adami HO; Grönberg H; Wiklund F; Green FR; Rayman MP
Cancer Res; 2008 Dec; 68(24):10171-7. PubMed ID: 19074884
[TBL] [Abstract][Full Text] [Related]
40. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
